Very quick comment on the German over 65s story.
1. Not a surprise, and same approach taken by FDA in the US (actually FDA more stringent still and haven't approved in younger people either yet).
2. Problem is NOT that efficacy shown to be low but that insufficient older people in the dataset to show either way. Additional trial is being run to address the data gap.
3. Not a concern scientifically: the UK justification was
(i) Good efficacy shown in other age groups
(ii) Excellent immune response measured in older people, equivalent to that in younger, and as good (actually better IIRC) than Pfizer. Efficacy comes from immune response.
MHRA and several other authorities worldwide believe this shows sufficient benefit/ risk to approve. EMA/FDA require formal efficacy data.
Regulatory agencies taking different views on this sort of issue is not unusual.
Main issue is communication for people elsewhere taking the jab, not the decision itself.
My parents are due for vaccination today, based on all of this I'm delighted whichever they get.